2C-T-4, also known as 4-isopropylthio-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
2C-T-4 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-T-4's dose as 8 to 20mg orally and its duration as 12 to 18hours. Its onset is 30minutes to 2hours and peak effects occur after 3hours. The effects of 2C-T-4 have been described and include psychedelic visuals among others. Shulgin devoted a chapter in the first part of PiHKAL to 2C-T-4, describing an intense "plus-four" experience on the Shulgin Rating Scale with a 12mg dose.
2C drugs are metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C drugs. This may result in overdose and serious toxicity.
2C-T-4 acts as a serotonin 5-HT<sub>2</sub> receptor agonist, including of the serotonin 5-HT<sub>2A</sub> receptor. The mechanism that produces 2C-T-4's hallucinogenic effects has not been specifically established, however it is most likely to result from 5-HT<sub>2A</sub> receptor activation in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.
2C-T-4 is the 2-carbon homologue of Aleph-4. The full chemical name is 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]-ethanamine. The drug has structural and pharmacodynamic properties similar to 2C-T-7 and 2C-T-19. A notable analogue of 2C-T-4 is the è-PEA compound è-2C-T-4.
The chemical synthesis of 2C-T-4 has been described.
Analogues of 2C-T-4 include 2C-T, 2C-T-2, 2C-T-7, and Aleph-4, among others.
2C-T-4 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991. Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
As of October 31, 2016, 2C-T-4 is a controlled substance (Schedule III) in Canada.
As of October 2015 2C-T-4 is a controlled substance in China.
2C-T-4 is added to the list of Schedule B controlled substances.
Sveriges riksdags health ministry classified 2C-T-4 as "health hazard" under the act (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Jul 15, 2007, in their regulation SFS 2007:600 listed as 2,5-dimetoxi-4-isopropyltiofenetylamin (2C-T-4), making it illegal to sell or possess.
As of July 9, 2012, 2C-T-4 is a Schedule I substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012.